OPERATING REVIEW CONTINUED In December 2025 Acadia received US Food and Drug Administration (FDA) approval of DAYBUE STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. The new powder formulation offers children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment, potentially facilitating treatment of a significant number of new patients from families who had declined to try or discontinued the liquid formulation. DAYBUE STIX is being launched on a limited basis in Q1 2026 and more broadly early in Q2 2026. The existing oral solution formulation will remain available. DAYBUE® (TROFINETIDE) FOR RETT SYNDROME 460 177 348 391 490 CY2023 (Apr -Dec) CY2024 CY2025 CY2026 Acadia Guidance DAYBUE Net Sales (US$m) 70 27 56 65 77 CY2023 CY2024 CY2025 CY2026E* Royalty to Neuren (A$m) +18–25% + 8–19% +12% +15% 0 0 026 dia ance m) 70 27 56 65 77 CY2023 CY2024 CY2025 CY2026E* Royalty to Neuren (A$m) + 8–19% +15% * Based on Acadia full year 2026 DAYBUE Net Sales Guidance of US$460490m, conservatively assuming North America royalty rates only (10% of DAYBUE net sales up to US$250m and 12% of DAYBUE net sales between US$250m and US$500m), and AUDUSD of 0.70 to 0.72 In March 2023, Neuren’s exclusive worldwide licensee for trofinetide, Acadia Pharmaceuticals (NASDAQ: ACAD), received FDA approval of DAYBUE® (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. On 17 April 2023, Acadia launched DAYBUE in the United States as the first ever approved treatment for Rett syndrome. Access to DAYBUE has been well supported by Medicaid and private health insurance payors. During 2025, Acadia activated named patient supply programs across multiple regions including Europe, the Middle East and Latin America. Growing, sustainable income to Neuren from DAYBUE® (trofinetide) in the United States plus international named patient programs Neuren Pharmaceuticals Limited Annual Report 2025 6
RkJQdWJsaXNoZXIy MjE2NDg3